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Abstract
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics.
However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and
Emergency Department accesses as well as expensive treatments.
The recent identification of different endotypes of asthma, based on the inflammatory pattern, has led to the
development of tailored treatments that target different inflammatory mediators. These are major achievements
in the perspective of Precision Medicine: a leading approach to the modern treatment strategy.
Omalizumab, an anti-IgE antibody, has been the only biologic treatment available on the market for severe
asthma during the last decade. It prevents the linkage of the IgE and the receptors, thereby inhibiting mast
cell degranulation. In clinical practice omalizumab significantly reduced the asthma exacerbations as well as
the concomitant use of oral glucocorticoids.
In the “Th2-high asthma” phenotype, the hallmarks are increased levels of eosinophils and other markers (such as
periostin). Because anti-IL-5 in this condition plays a crucial role in driving eosinophil inflammation, this cytokine
or its receptors on the eosinophil surface has been studied as a potential target for therapy.
Two different anti-IL-5 humanized monoclonal antibodies, mepolizumab and reslizumab, have been proven effective in
this phenotype of asthma (recently they both came on the market in the United States), as well as an anti-IL-5
receptor alpha (IL5Rα), benralizumab.
Other monoclonal antibodies, targeting different cytokines (IL-13, IL-4, IL-17 and TSLP) are still under evaluation,
though the preliminary results are encouraging.
Finally, AIT, Allergen Immunotherapy, a prototype of Precision Medicine, is considered, also in light of the recent
evidences of Sublingual Immunotherapy (SLIT) tablet efficacy and safety in mite allergic asthma patients.
Given the high costs of these therapies, however, there is an urgent need to identify biomarkers that can predict
the clinical responders.
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Background
The evolution of asthma treatment was described by von
Mutius & Drazen [1] and Bjermer [2] who pointed out
how the new treatments were paralleled to the under-
standing of new pathogenetic mechanisms. This paper in
a series by the WAO Collaborative on Severe Asthma
(COSA) proposes a concise revision of how to approach
and treat the eosinophilic pulmonary disorders in light
of the new knowledge on the topic.
Undoubtedly, severe asthma is the most impacting
“Pulmonary Eosinophilic Disorder” in terms of preva-
lence. Although severe asthma accounts for just 5 to
10% of total patients with asthma, it still represents a re-
markable number of patients [3]. We should consider
that not all severe asthmatic patients have eosinophilic
inflammation; in fact, different patient phenotypes and/
or endotypes are considered nowadays. This is the correct
approach in selecting and diagnosing patients who are
eligible for current and pending biologics for asthma
treatment [4].
The careful and appropriate selection of patients is also
the basis for successful allergen immunotherapy (AIT).
Actually, asthma was not intended as a target disease for
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AIT, for a long time. In fact, asthma guidelines are not
considering it either. The recent evidence of house dust
mite tablets in both Europe [5, 6] and the United States
[7] strongly supports the efficacy of sublingual AIT in
asthma. The clear evidence will prompt the inclusion of
AIT in asthma guidelines, always keeping in mind the
concept of the evidence related to the single product(s)
and not as a class effect, as reported recently in a state-
ment of the World Allergy Organization on this specific
issue [8].
How biologics or other treatment can target eosinophilic
inflammation is the focus of this paper.
Pharmacologic treatment of eosinophilic
disorders
Introduction
Asthma is a chronic inflammatory disorder of the airways
characterized by variable air flow obstructions and tissue
remodeling, mediated by a variety of inflammatory media-
tors and immune cells, including mast cells, several T cell
subpopulations, eosinophils, basophils and neutrophils
[9]. There is now recognition that distinct subgroups of
asthma termed endotypes exist. An endotype, is “a subtype
of a condition defined by distinct pathophysiological
mechanisms” [10]. The American Thoracic Society (ATS)/
European Respiratory Society (ERS) Task Force on Severe
Asthma has defined this condition as asthma requiring
global initiative for asthma step 4 or 5 treatment (high-
dose inhaled corticosteroids and long-acting β-agonists or
leukotriene modifier or tiotropium). Treatment options
for severe asthma are limited and include Omalizumab,
indicated in a selected phenotype of patients with high
serum IgE levels [11], oral glucocorticoids and, more re-
cently, tiotropium [12, 13].
Current research in severe asthma therapy is focused
on the development of treatments that target specific
components of airway inflammations. “Th2-high” asthma
is characterized by increased levels of Type 2 inflamma-
tion in the airways including eosinophilia, increased num-
bers of airway mast cells and overexpression of periostin
[14]. “Th2-high asthma” is characteristic of responsive to
inhaled corticosteroids (ICS), whereas “Th2-low” asthma
(classified as having low levels of type 2 inflammation) is
not [15].
Several groups have reported cluster analyses of pa-
tient cohorts to investigate disease endotypes [16–21].
However, these studies are often limited by a lack of
robust statistical validation or have generated clusters
the identities of which are dominated by predominantly
clinical parameters. Recently, large severe asthma co-
horts were analyzed by using real-word assays already
accessible to clinicians. This study identified six clusters
based on blood and induced sputum measures [22]. The
identification of additional biomarkers will provide more
insights in the definition/selection of phenotype(s) eligible
to a single therapy [4].
Pharmacologic treatment of severe asthma
Pharmacologic treatment of severe asthma is based on the
association of one of different medium- or high- dose
inhaled corticosteroids (ICS) (Budesonide, Fluticasone,
Beclomethasone, Ciclesonide and others) and long-acting
β-adrenergic bronchodilators (LABA) (Formoterol, Salme-
terol, Vilanterol, Indacaterol, and others). This approach
has shown efficacy in the management of severe asthma
and is recommended by Global Initiative for Asthma
(GINA) guidelines. Patients with severe asthma may also
be receiving as-needed short-acting β agonists (SABA).
Racial differences in the response to β-agonists have also
been reported [23].
Some patients with severe asthma remain symptomatic
despite maximal recommended treatment. Tiotropium, a
long-acting inhaled anti-cholinergic agent, significantly
improves lung function in severe asthma [24–26]. There
is some evidence that long-acting muscarinic antagonists
(LAMA) added to ICS show some benefits over LABA
plus ICS on some measures of lung function [27].
The leukotrienes modifier Montelukast is not as effect-
ive as LABAs when added to ICS in preventing asthma
exacerbation or improving symptoms [28]. Whether in-
dividuals with the phenotype of aspirin-sensitive asthma
respond better to leukotriene inhibitors than those with-
out aspirin sensitivity has not been addressed.
Roflumilast, a selective phosphodiesterase 4 (PDE4) in-
hibitor, provides some improvements in lung function in
patients with moderate-to-severe asthma [29]. In this
study Roflumilast was used in combination with Monte-
lukast in patients with uncontrolled asthma despite a
moderate dose of ICS and LABA. This pilot study de-
serves additional investigations.
Bronchial thermoplasty (BT) was proposed as a tech-
nique to reduce airway stiffness and excessive narrowing
[30]. Although the mechanism of action has not been
elucidated, some positive outcomes in asthma have been
reported [31, 32]; recently, a positive perspective of cost/
effectiveness of this treatment has been envisaged [33].
Treatment of eosinophilic asthma
Increasing evidence suggests that airway neutrophilia and
eosinophilia represent two distinct inflammatory networks
that contribute separately to severe asthma symptoms
[16]. Interestingly, more than one eosinophilic or neutro-
philic clusters were identified. One cluster was character-
ized by high serum periostin and IgE levels. The most
neutrophilic disease was characterized by strong correl-
ation between sputum YKL-40 and IL-8 levels, in addition
to several markers of neutrophilic inflammation. Like
others [34], they found no evidence of dysregulation of
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airway IL-17 in any subgroup, implying this cytokine
might not be a promising target [35].
Targeting IL-5 or IL-5Rα is an appealing approach to
the treatment of severe eosinophilic asthma [36]. Two
different humanized anti-IL-5 monoclonal antibodies
(Mepolizumab and Reslizumab) have been shown safety
and efficacy in clinic trials of severe asthma. Mepolizumab
has a glucocorticoid-sparing effect, reduces exacerbations
and improves FEV1 and ACQ-5 score [37, 38]. Mepolizu-
mab has been approved by FDA and EMA as an add-on
maintaining treatment for adults with severe eosinophilic
asthma. More recently, FDA approved Reslizumab with
the same indication.
Reslizumab, a humanized anti-IL-5 monoclonal anti-
body, reduces blood and sputum eosinophils and im-
proves FEV1 and ACQ score in patients with severe
asthma [39]. The FDA recommended approval for
Reslizumab in 2015 as an add-on maintaining treat-
ment for adults with severe eosinophilic asthma.
Benralizumab is a humanized monoclonal antibody
anti-IL-5Rα which binds to IL-5Rα on human eosinophils
and basophils. Benralizumab improved lung function
asthma control and ACQ-6 score compared to placebo
in severe eosinophilic asthmatics [40]. A single-dose of
Benralizumab administered to patients with severe
asthma resulting in emergency department reduced the
exacerbations during the following 3 months [41].
Targeting GATA-3, an important transcription factor
of the Th2 pathway, may be beneficial in a subgroup of
severe asthmatic patients. A novel DNA enzyme that
cleaves and inactivates GATA-3 messenger RNA (mRNA)
has been shown to inhibit the late asthmatic response to
allergens [42].
Asthma is a prominent clinical hallmark of eosino-
philic granulomatosis with polyangiitis (EGPA), previ-
ously called Churg-Strauss syndrome. In a small group
of steroid-dependent EGPA patients, anti-IL-5 mab,
namely Mepolizumab, had a glucocorticoid sparing ef-
fect without improving the pulmonary function [43]. In a
pilot study we have found that Omalizumab has a
glucocorticoid-sparing effect while decreasing blood eosin-
ophils and improving lung function in EGPA patients [44].
Other approaches with biologics are specifically re-
ported in details in another section of this document.
We wish here to underline how in the recent years a sub-
stantial improvement in therapeutic options for treating
eosinophilic disorders became available, as summarized in
Table 1, which shows examples of targeted therapies in
preclinical or clinical development in severe asthma.
Monoclonal antibodies in severe asthma
Introduction
Severe refractory asthma is present when asthma remains
uncontrolled despite maximal treatment [45]. The release
of pro-inflammatory proteins mediates the inflammatory
response associated with severe asthma. The identification
of these mediators has resulted in the strategy of targeting
these molecular pathways with monoclonal antibodies
(hMab) for the treatment of severe asthma.
Anti-IgE monoclonal antibody
The initial hMab (Omalizumab) developed for the treat-
ment of asthma was directed against immunoglobulin E
(IgE). Omalizumab prevents cross-linkage of the high-
affinity IgE receptor, FcεRI, thereby inhibiting the degranu-
lation, pro-inflammatory mediator release and production
of newly formed lipid mediators from mast cells. It is
effective in reducing oral corticosteroid dependence and
exacerbation rates in allergic asthmatics with an elevated
IgE level [46]. Omalizumab treatment rarely causes ana-
phylaxis [47], and an initial concern about increases in ma-
lignancy with its use was refuted in a large safety study
[48]. Ligelizumab is another anti-IgE hMab, currently
under development, which has a higher affinity binding for
IgE when compared with Omalizumab. Allergen-induced
bronchoconstrictor responses and skin prick test responses
were also more effectively suppressed by Ligelizumab com-
pared with Omalizumab [49].
Anti-IL-5 monoclonal antibodies
IL-5 is essential for the development, differentiation, recruit-
ment, activation and survival of eosinophils. Two hMabs
have been developed which bind IL-5 and prevent its en-
gagement with its receptor. These are Mepolizumab and
Reslizumab. Both have been shown to reduce severe asthma
exacerbations, improve FEV1, and allow oral corticosteroid
reduction in severe asthmatics with persisting airway eosino-
philia [38, 39, 50, 51]. Another hMab, Benralizumab, binds
to IL-5R alpha and causes (as it is afucosylated) enhanced
antibody-dependent cell-mediated cytotoxicity of both baso-
phils and eosinophils [40, 52]. Both Mepolizumab and Resli-
zumab are now approved as add on therapy in patients with
severe eosinophilic asthma.
Anti-IL-4/IL-13 monoclonal antibodies
IL-4 and IL-13 are type 2 cytokines that have a variety of
effects, including immunoglobulin class switching for
the production of IgE, enhanced airway smooth muscle
contractility, eosinophil recruitment and airway mucus
production. Two hMabs (Lebrikizumab and Tralokinu-
mab), which directly bind IL-13, are in clinical develop-
ment. Both have been demonstrated to improve lung
function and possibly reduce asthma exacerbations, but
only in patients with severe asthma with biomarker evi-
dence of a type-2 phenotype, demonstrated by elevated
serum periostin levels or elevated IL-13 levels in sputum
[53, 54].
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Table 1 Examples of Targeted Therapies in Preclinical or Clinical Development in Severe Asthma
Strategy Target Drug Biological or Clinical Effects References
Cell surface protein Siglec-8 Anti-Siglec 8
monoclonal antibody
Apoptosis of eosinophils Nutku et al., Blood 101: 5014,
2003 [107]
Bochner et al., Clin. Exp. Allergy
39: 317, 2009 [108]
CD172a Inhibitor of signaling Verjan Garcia et al., J. Immunol. 187:
2288, 2011 [109]
CD300a Activation of inhibitory receptor Munitz et al., Blood 107: 1996, 2006
[110]
Immunoglobulin-
like receptor B
Munitz et al., Blood 111: 5694, 2008
[111]
α4β1, α4β7 Natalizumab Increase blood eosinophils and inhibits
their tissue accumulation
Abbas et al., Neurology 77: 1561,
2011 [112]
α4β7 integrin Vedolizumab No effect Soler et al., JPET 330: 864, 2009
[113]
α4β7 , αEβ7 Etrolizumab Unknown
CCR3 GW766944 Block chemokine-induced eosinophils
in vitro; no effect in vivo
Neighbour et al., Clin. Exp. Allergy
44: 508, 2014 [114]
CXCR2 SCH527123 Reduce blood and sputum neutrophils Nair et al., Clin. Exp. Allergy 42: 1097,
2012 [115]
CD52 Alemtuzumab Deplete eosinophils in vivo Wechsler et al., JACI 130: 563, 2012
[116]
CD131 CSL311 Unknown
CRTH2 0C000459 Reduce tissue eosinophils Pettipher et al., Allergy 69: 1223, 2014
[117]
ACT-453859 CRTH2 blockade Géhin et al., J. Clin. Pharmacol. 55: 787,
2015 [118]
EMR1 Afucosylated anti-EMR1
monoclonal antibody
Deplete primate eosinophils Legrand et al., JACI 133: 1439, 2014
[119]
Interleukin-4Rα Dupilumab Reduce airway eosinophils NCT01312961
Interleukin-4Rα AMG-317 Do not reduce airway eosinophils Corren et al., Am. J. Resp. Crit. Care Med.
181: 788, 2010 [120]
H4 Receptor UR-63325
JNJ 28610244
Salcedo et al., Front Biosci 5: 178, 2013
[121]
Dib et al., JLB 96: 411, 2014 [122]
Soluble mediator
antagonist
Eotaxin-1 Bertilimumab Inhibit Eotaxin-1 mediated eosinophil
activation in vitro
Ding et al., Curr. Opin. Investig. Drug 5:
1213, 2004 [123]
IgE Omalizumab Reduces eosinophils at sites of allergic
inflammation and peripheral blood
Detoraki et al., J. Asthma 53: 201, 2016
[44]
IL-4 Altrakincept
Pascolizumab
Pitrakinra
Reduce eosinophils at sites of allergic
inflammation
Borish et al., Am. J. Resp. Crit. Care Med.
160: 1816, 1999 [124]
Hart et al., Clin. Exp. Immunol. 130: 93,
2002 [125]
IL-13 Tralokinumab
Lebrikizumab
Anrukinzumab
RPC4046
QAX576
Reduce eosinophils in blood and at
sites of allergic inflammation
Blanchard et al., Clin. Exp. Allergy 35:
1096, 2005 [126]
Maselli et al., J. Asthma Allergy 8: 87,
2015 [127]
Interleukin-17RA Brodalumab No effect Busse et al., Am J Respir Crit Care Med
188: 1294, 2013 [35]
TSLP AMG157 Reduce eosinophils in blood and at
sites of allergic inflammation
Gauvreau et al., NEJM 370: 2102, 2014
[57]
Transcription factor GATA3 SB010 Reduce IL-5 and late asthmatic
response after allergen challenge
Krug et al., NEJM 372: 1987, 2015 [42]
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IL-4 and IL-13 share part of the heterodimeric recep-
tor complex (IL-4Rα). Dupilumab is a mAb to IL-4Ra
that inhibits both IL-4 and IL-13 signaling. In an early
phase clinical trial, treatment with Dupilumab allowed
reduction of maintenance treatment with inhaled cor-
ticosteroid (ICS) and long-acting inhaled beta-agonist
(LABA) treatment without loss of asthma control in
patients with elevated blood eosinophil levels [55].
Anti-Thymic Stromal Lymphopoietin (TSLP) monoclonal
antibodies
TSLP is an interleukin-7-related cytokine secreted by
airway epithelial cells. TSLP activates dendritic cells to
release chemokines that recruit and activate Th2 cells.
TSLP is increased in the airway epithelium of patients
with severe asthma [56]. AMG 157, an anti-TSLP hMab,
attenuated allergen-induced early and late asthmatic re-
sponses in mild allergic asthma. It also reduced baseline
blood and sputum eosinophil counts and fractional ex-
haled nitric oxide (FeNO) concentrations before allergen
challenge [57]. This suggests that TSLP is constitutively
released in the airways of allergic asthmatic, and as it is
“upstream” of the events leading to the release of type-2
cytokines, IL-5 and IL-13, its blockade may provide simi-
lar clinical benefit to blockade of both of these cytokines.
Anti-IL-17 monoclonal antibodies
Th17 cells are CD4 T cells that express IL-17A, −17E,
−17 F, and −22, and are able to mediate neutrophil activa-
tion. Overproduction of these IL-17 cytokines has been
demonstrated in patients with severe neutrophilic asthma
disease [58, 59]. Brodalumab, is an anti-17 receptor hMab,
which had no effect on asthma control scores, symptom-
free days, and FEV1 in patients with inadequately
controlled moderate-to-severe asthma, who were also
receiving inhaled corticosteroid therapy [35].
Anti-TNF αlpha monoclonal antibodies
Initial studies in severe asthma using hMabs which bind
TNFα showed promise [60, 61]; however, an increase in
infections and malignancies during treatment with one
anti-TNF hMab, Golimumab, when compared with placebo
has halted further studies in asthma of this class of anti-
Th1 targeted therapies [62].
Conclusions
Asthma is a heterogeneous disease and this is particularly
true of severe refractory asthma. Biologic treatments have
shown promise in several phenotypes of severe asthma.
Anti-IgE hMabs are effective in severe allergic asthma and
hMabs directed against IL-5 in severe eosinophilic asthma,
particularly in reducing severe asthma exacerbations.
Other approaches directed against the IL-4/IL-13 and
TSLP are under investigation.
Specific immunotherapy in asthma, an example of
personalized medicine?
Background and introduction
In the available guidelines and systematic reviews it is
stated that allergen immunotherapy (AIT) is not specific
for the disease (rhinitis/asthma) but only for the allergen
causing the disease itself [63]. This is reasonably based
on the knowledge of the pathophysiology of allergic dis-
eases and of the mechanisms of action of AIT [64].
Nonetheless, the efficacy and safety aspects tend to be
kept separate for asthma and rhinitis, as testified by
several large reviews and meta-analyses [65–72]. Allergic
asthma, in particular, remains one of the most important
matters of debate for the use of AIT [73, 74]. From a
historical point of view, the scepticism towards AIT in
asthma is mainly due to the reports of severe (or fatal)
reactions in asthmatic patients, when only the subcuta-
neous route (SCIT) was available [75–78]. The perspec-
tive partially changed after the sublingual route (SLIT)
of administration became available, largely used and
studied. In fact, with SLIT a satisfactory efficacy could
be achieved also in asthmatic patients, and no severe ad-
verse event or fatality was reported [79, 80]. In addition,
it should be taken into account that most of the severe
events (and rare deaths in asthmatic patients), were de-
scribed in the U.S. surveys, where high concentrations of
allergens and mixtures of allergens were used [81].
It is also true that none of the trials evaluating asthma
symptoms was adequately designed and reported [73, 74]:
none of the trials had a sample size calculation and a
power analysis based on asthma symptoms or pulmonary
functions as primary outcome. Moreover, there is no
formal consensus on which measurement parameters
for asthma should be chosen. Asthma symptoms, res-
cue medications, combined scores, asthma-free days,
forced expiratory volume in one second (FEV1), and
asthma exacerbations are all equally reasonable choices.
In this regard, objective functional pulmonary measure-
ments were carried out only sporadically. More re-
cently, some clinical trials were specifically designed for
asthma, and took into account specific asthma-related
parameters (such as the use of inhaled corticosteroids
or the exacerbation rate). Finally, we should consider
that isolated allergic asthma without rhinitis is rare,
whereas asthma is present in more than 30% of patients
with rhinitis [82]. In fact, the majority of recent clinical
trials were performed in allergic rhinitis (with or with-
out allergic asthma), and very few trials were specific-
ally designed to evaluate the effect of AIT in asthma
alone. Nowadays, the principal questions are: is AIT ef-
fective in asthma or does AIT provide an adjunct bene-
fit in asthma?; does AIT worsen asthma?; is asthma an
absolute contraindication and a risk factor for adverse
events during AIT?
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SCIT and SLIT in asthma: overview of clinical trials
Clinical efficacy
It is not possible to describe in detail herein each of the
studies of AIT in asthma, and summaries of data in
literature are already available [65–74]. Thus we are
quoting only the meta-analyses which specifically dealt
with asthma, as a comprehensive example of the results
achieved so far (with their limitations).
There are numerous clinical trials of SCIT which
considered asthma, most of them published before
1990 and generally including small numbers of patients.
The available largest meta-analysis [69] included 88
randomized controlled trials (70 of which placebo-
controlled) published between 1954 and 2009. The
methodological quality, was low to moderate, and very
few trials achieved the maximum score. Symptom
scores were reported in 35 studies, medication scores
in 21 and 20 studies had a pulmonary function meas-
urement. This meta-analysis reported a borderline
reduction in symptoms with mite allergens, but an
apparent effect with pollens. The effect on asthma
medication intake was overall significant. No change in
pulmonary function could be seen, whereas a decrease
in allergen-specific bronchial response was consistently
shown.
The number of randomized controlled trials for SLIT is
quite large and, therefore, some meta-analyses were
performed. The first meta-analysis specifically focusing
the effect of SLIT in asthma was published in 2006
[65], and analysed 25 trials with 1076 patients (adults
and children). This meta-analysis reported a significant
difference between SLIT and placebo for categorical
outcomes (better / unchanged / worsened), but no differ-
ence using the symptom or medication scores for asthma.
On the other hand, the combined symptom score of
asthma-rhinitis were clearly in favour of SLIT. Nonethe-
less, there was a high heterogeneity, which limits at some
extent the positive conclusions. Another meta-analysis
[67] dealt with paediatric asthma (patients < 18 years) and
included nine trials with 441 patients. The results, accord-
ing to the mean standardized difference demonstrated a
significant reduction in both symptoms (P = 0.02) and
medication use (P = 0.007) vs. placebo. Also in this case a
high degree of heterogeneity was found, due to the vari-
able inclusion criteria, scoring systems and regimens. Two
other meta-analyses, one restricted to mite extracts [70]
and one to grass extracts [71] were also published The
meta-analysis for dust mite included nine trials with
asthma symptoms/medications and the results showed a
significant reduction vs placebo in both symptom scores
(P = 0.02) and medication intake (P = 0.02). The meta-
analysis for grasses did not report specific results for
asthma. Of note, for SCIT only one “large trial” was
performed [83].
Only few recent studies [5, 84] were specifically de-
signed to assess asthma related outcomes. Zielen et al.
[84] evaluated 65 asthmatic children (GINA step 2–3),
randomized to inhaled fluticasone alone or plus mite-
SCIT. After 2 years of treatment, the dose of inhaled
fluticasone to maintain asthma controlled was halved in
the active versus the control group. In another study
[5] performed in >600 mite-allergic adolescents and
adults, with a dose-ranging design, a significant reduc-
tion in the dose of inhaled corticosteroids could be
demonstrated with the highest dose of SLIT. Wang et
al. [85], in 484 adult subjects receiving mite-SLIT in a
randomized controlled trial, found a significant differ-
ence in asthma control only in moderate asthma, but
not in mild disease. This latter finding is in line with
previous observations: if asthma is per se well con-
trolled by drugs, or patients are almost symptom-free,
no or marginal effects of AIT can be appreciated [86].
Safety
In the studies published so far available, the frequency of
SCIT-induced systemic reactions (SRs) is largely variable
according to the allergen, the administration schedule,
standardization of the extract, the maintenance dose given
and the severity and type of disease. Another main prob-
lem is the lack of a universally accepted classification/
grading of the adverse events. This problem has recently
been addressed by the World Allergy Organization with
the proposal of new classification and grading systems [87,
88]. Finally, most data on systemic side effects come from
small controlled studies, whereas only large-scale surveys
can assure reliable data on the prevalence, characteristic
and severity of side effects. The majority of the data we
have available on the safety of SCIT derive from the large
surveys performed in the United States [76–78, 89]. Over-
all, these surveys recorded about 50 deaths over a 50-year
period with a risk of one death every 2.500.000 injections
and one near-fatal reaction per million injections. Again,
it is important to remember that the clinical practice of
SCIT in the United States is different from Europe, as
mixtures of multiple allergens are commonly used [81].
Thus, caution should be applied in transferring the USA
data to other countries. Less data are available for Europe.
After the well-known report of 26 deaths in UK in 1986
[75], probably ascribable to incorrect practice in most
cases, fatalities have become extremely rare, and no report
was released in the last decade. Several surveys [90–93],
reported an overall rate of systemic reactions of about 5%
of patients. The more recent multicentre survey [93] re-
ported that systemic reactions were slightly more frequent
in rhinitis with asthma than in rhinitis alone.
Overall the safety of SLIT is superior to that of SCIT
[79, 80]. This is testified to by the reports of “large trials”
including hundreds of patients, and no fatality has been
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so far reported with SLIT in more than 30 years of clin-
ical trials and practical use. Interestingly, a study by Dahl
et al. [94] specifically assessed the safety of SLIT in
asthma. More than 100 grass-allergic asthmatics were
enrolled and studied before the pollen season. The num-
ber of side effects linked to asthma (wheezing cough, dry
throat, dyspnoea, increased bronchial secretion) was
similar between the active and placebo group, and there
was no evidence of asthma aggravation. In general, SLIT
induced asthma only rarely. In another study, the pro-
gressive increase of doses increased local AEs, but not
asthma symptoms [95].
Despite the overall rarity of deaths the surveys agreed
on the fact that uncontrolled asthma is the most prom-
inent risk factor for fatalities and severe adverse events,
including asthma itself. Thus, asthma, if well controlled
it is not an absolute contraindication to AIT [96].
The additional effects of AIT in asthma
There is another important aspect to be considered
when evaluating AIT in asthma, that is the preventive
effect. Rhinitis is the major risk factor for the develop-
ment of asthma [90, 97] and AIT, as biological response
modifier can interfere with the progression from rhinitis
to asthma. Indeed, the preventative effect of AIT (reduc-
tion in the risk of developing asthma) was suggested
about 50 years ago in an observational open prospective
study [98], but it was confirmed in more rigorous trial
only in the last decades [99–101]. The Preventative Al-
lergy Treatment study enrolled 205 children (aged 6–10
years) suffering from allergic rhinitis. They were ran-
domized to either drug therapy alone or drugs plus
SCIT. After 3 years, the SCIT-treated patients had devel-
oped significantly less asthma than the control group,
with an odds ratio of 2.5. Interestingly, the beneficial ef-
fect of SCIT lasted several years after discontinuation,
and also at the 10-year follow-up there were significantly
less patients with asthma in the formerly SCIT-treated
group [99]. Concerning SLIT there are two studies sup-
porting the possible disease-modifying effect of the treat-
ment. The first open controlled study [100] involved 113
children aged 5–14 years suffering from seasonal rhinitis
due to grass pollen. They were randomly allocated to
medications plus SLIT or medications only. After 3 years,
8/45 SLIT subjects and 18/44 controls had developed
asthma, with a relative risk of 3.8 for untreated patients.
Another randomized open controlled trial [101] involved
216 children (age 5–17 years) suffering from rhinitis with/
without intermittent asthma. They were randomly allo-
cated 2:1 to drugs plus SLIT or drugs only, and followed
for 3 years for the presence of persistent asthma. The
prevalence of persistent asthma was 2/130 (1.5%) in the
SLIT group and 19/66 (30%) in the control group, with a
number to treat of 4. These data support the need for
further randomized blinded trials of the potential long
term benefits of SLIT in the development of asthma [102].
AIT as “personalized” or “precision” medicine
The current view in medicine is that of a “personalized” or
“precision” approach. The “blockbuster approach” (i.e. one
size fits all) cannot be currently used with many of the
very expensive treatments available, where the best cost/
effective treatment should be provided. The “precision
medicine” can be defined as a structural model aimed at
customizing healthcare at best, with medical decisions,
practices, and/or products tailored on an individual pa-
tient (Fig. 1) [103]. In other terms, the underlying mecha-
nisms of a given disease should be clearly defined. Then
the biomarkers for that disease should be identified and,
subsequently, the targeted therapeutic approach can be
chosen. This implies that the response to a given therapy
can be predicted a priori, by means of specific bio-
markers. AIT represents a good paradigm of this ap-
proach. In such case, we have: a) the clinical aspects
well defined and easy to diagnose; b) the mechanisms
(IgE-mediated) are well identified:; c) reliable diagnostic
tests are available, including the molecular aspects
[103]; d) AIT is allergen-oriented [104] (Fig. 2). None-
theless, we still need biomarkers predictive of the ex-
pected efficacy and, consequently, the identification of
the eligible patients, with direct economic implications.
Certainly we would need a more spread knowledge on
molecular allergy, to be ourselves more adherent to the
definition of personalized medicine. Moreover, a clear
characterization and definition of commercial products
for vaccination is also urgently needed. A precision medi-
cine requires precision approaches, whereas nowadays, for
Fig. 1 Current and possible future approach in prescribing AIT for
respiratory allergy (SPT = skin prick test: sIgE = specific IgE) (Modified
from Canonica GW et al., World Allergy Organ J 2015) [103]
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many commercial products the characterization remains
poor, and in some cases an experimental proof of efficacy
is lacking [8].
Conclusions
In recent years, evidence-based medicine has become
more and more important, and almost all guidelines
and recommendations are prepared according to well
accepted evaluation systems such as the GRADE [105].
The evidence based criteria firstly require that the
methodology of trials is adequate, and this is not always
the case for AIT studies. Almost all the available ran-
domized controlled trials suffer from methodological
limitations: small number of patients, absence of a sam-
ple size calculation based on a definite outcome, large
variability in methodology. This even better applies to
asthma studies, where only few trials were adequately
powered [106]. Based on the earliest clinical trials
xand surveys, only uncontrolled asthma remains the
main contraindication to AIT, whereas in controlled
allergic asthma it can be confidently used, together
with medications, when the causal role of the allergen
(pollens, mite or pets) is clearly confirmed. The rec-
ommendation of not giving SIT in patients with se-
vere uncontrolled asthma remains valid for both SCIT
and SLIT. When asthma is the only manifestation of
allergic disease, AIT may exert a beneficial effect, at
least by reducing the need for medications and redu-
cing associated bronchial responsiveness. This does
not imply that AIT is to be used as the primary
therapeutic approach in adults or indeed in children,
where highly effective drugs (i.e. inhaled steroids) are
currently available. Future studies are needed to focus
patients with moderate/severe asthma, where asthma
is the primary outcome. Long-term benefits after dis-
continuation need to be evaluated as well.
Conclusions
Although the prevalence of severe asthma is relatively low,
it accounts for 50% of the global costs of the disease, and
it is responsible for the majority of the hospitalizations
and Emergency Department accesses. For these reasons
research has been focused on this condition.
According to the GINA Guidelines the pharmacologic
treatment is currently based on the combination of a
high dose of ICS with LABA. In non-responsive patients
the addition of anti-cholinergic drugs such as tiotropium
can be an effective option.
However the recent identification of different endotypes
of asthma, based on the inflammatory pattern has led to a
different approach to the treatment, which targets the
specific components of the inflammation. Omalizumab
prevents the cross-linkage of the IgE and the high-affinity
IgE receptors (FcεRI), thereby inhibiting mast-cell de-
granulation. Its efficacy in reducing exacerbations as well
as the oral use of CS has been demonstrated in severe al-
lergic asthma.
Besides this allergic phenotype the “Th2-high asthma”
is characterized by increased levels of Type 2 inflamma-
tion in the airways including eosinophilia and overex-
pression of periostin. In this condition IL-5 has a pivotal
role in driving eosinophilic inflammation and therefore
targeting IL-5 or Il-5R alpha is an attractive biologic
approach.
Two different humanized anti-IL-5 monoclonal anti-
bodies (mepolizumab and reslizumab) have been proven
Fig. 2 AIT as a model of “precision medicine” (Modified from Passalacqua G et al., Clin Molecular Allergy 2015) [104]
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effective and safe in severe asthma, in patients with more
severe eosinophilic inflammation. In addition, benlarizu-
mab, a humanized antibody anti IL-5R alpha, which binds
the receptors on human eosinophils and basophils, has
also significantly reduced the exacerbations in patients
with eosinophilic severe asthma over a three-month treat-
ment period.
Several monoclonal antibodies targeting other proin-
flammatory interleukins (IL-4 and IL-13) are still under
evaluations.
The anti-IL-17 receptor monoclonal antibody, brodalu-
mab, is currently the only biologic treatment under evalu-
ation in neutrophilic asthma.
With the potential use of these biologic drugs a tailored
approach in severe asthma will be possible in the future.
However, given the high costs of these treatments, the
economical sustainability of this approach needs a parallel
investigation of clinical and/or biological marker of effi-
cacy of these drugs in order to use in every case the right
treatment in the right patient.
Key points
– The prevalence of severe asthma is low (5-10%), but
it accounts for most of ER admissions and
hospitalizations due to the disease. Moreover, this
condition is responsible for 50% of the costs of the
disease.
– The knowledge of the biological mechanisms of the
inflammation underlying the disease has led to a
different approach of the treatment, based on the
use of monoclonal antibodies which can interfere
with the proinflammatory cytokines.
– Omalizumab, an anti-IgE monoclonal antibody, sig-
nificantly reduces exacerbations and the use of oral
glucocorticoids.
– In Th2-high asthma eosinophil and IL-5 have a pivotal
role. Encouraging results have been reported in
studies where patients with severe eosinophilic
asthma were treated with anti-IL-5 (mepolizumab
and reslizumab) or an anti IL-5Rα (benralizumab)
antibodies.
– Anti-IgE monoclonal antibody (omalizumab) is
established as a treatment option for severe allergic
asthma.
– Anti-IL-5 monoclonal antibodies (mepolizumab;
reslizumab) are approved for the treatment of severe
eosinophilic asthma.
– Anti-IL-13, anti-IL4Rα and anti-TSLP monoclonal
antibodies are currently being studied for severe
eosinophilic asthma.
– Other biologics targeting different mechanisms are
currently under investigation and will soon be
available.
– Given the high costs of these therapies, there is a need
to identify clinical and/or biological markers which
can select positive responders to these treatments
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